Martin P. Schwalm

Nov 25, 2024 | nature.com | Martin P. Schwalm |Johannes Dopfer |Adarsh Kumar |Francesco Greco |Nicolas Bauer |Frank Lohr | +18 more

AbstractRecent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community.

Apr 18, 2024 | nature.com | Martin P. Schwalm |Krishna Saxena |Susanne Müller

AbstractThe rational development of small-molecule degraders (e.g., proteolysis targeting chimeras) remains a challenge as the rate-limiting steps that determine degrader efficiency are largely unknown. Standard methods in the field of targeted protein degradation mostly rely on classical, low-throughput endpoint assays such as western blots or quantitative proteomics.

Oct 4, 2023 | biorxiv.org | Martin P. Schwalm |Adarsh Kumar |Francesco Greco |Johannes Dopfer

AbstractRecent successes in developing small-molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community.

Jun 23, 2023 | cell.com | Martin P. Schwalm |Andreas Krämer |Stefan Knapp

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.